Chlorothiazide
FDA-approved product (suspension, oral), marketed as Chlorothiazide, Diuril, Chlorothiazide Sodium.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiovascular disease
- Chronic kidney disease
- Congestive heart failure
- Edema
- Glomerulonephritis
- Heart failure
- Hypertension
- Nephrotic syndrome
- Preeclampsia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Thiazides, plain; Thiazides, combinations with psycholeptics and/or analgesics
- FDA pharmacologic class
- Thiazide Diuretic FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA37.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli33.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae12.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis68.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Chlorothiazide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- AmisulprideExisting use: Nausea and vomiting, Post operative nausea and vomiting, Psychosis66.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ItraconazoleExisting use: Aspergillosis, Blastomycosis, Candidiasis and 4 more66.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Dantrolene SodiumExisting use: Cerebral palsy, Fever, Malignant hyperthermia and 4 more66.6% AI-predicted activityagainst M. tuberculosis12 registered studies
- LurbinectedinExisting use: Cancer, Neoplasm, Small cell lung carcinoma66.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Methixene HydrochlorideExisting use: Parkinson disease66.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- Cisapride MonohydrateExisting use: Gastrointestinal disease66.5% AI-predicted activityagainst M. tuberculosis5 registered studies
- Angiotensin Ii AcetateExisting use: Cardiovascular disease, Hypotension, Septic shock and 1 more66.3% AI-predicted activityagainst M. tuberculosis10 registered studies
- QuazepamExisting use: Insomnia66.3% AI-predicted activityagainst M. tuberculosis1 registered study
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more66.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TerconazoleExisting use: Triazole derivatives66.2% AI-predicted activityagainst M. tuberculosis10 registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma66.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Lumateperone TosylateExisting use: Psychosis, Schizophrenia65.8% AI-predicted activityagainst M. tuberculosis6 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients
NCT02172586 · start 2000-01
Registered record
- Registry ID
- NCT02172586
- Conditions
- Hypertension
- Interventions
- Telmisartan; Losartan; Hydrochlorothiazide
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2000-01
- Completion
- Not recorded
- Enrolment
- 363
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionTelmisartan; Losartan; HydrochlorothiazidePhasePhase 4Registry statusCompletedA Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension
NCT03276598 · start 1999-11-25
Registered record
- Registry ID
- NCT03276598
- Conditions
- Hypertension; Pharmacogenetics
- Interventions
- Amlodipine; Bisoprolol; Hydrochlorothiazide; Losartan; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 1999-11-25
- Completion
- 2004-04-01
- Enrolment
- 233
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertension; PharmacogeneticsInterventionAmlodipine; Bisoprolol; Hydrochlorothiazide; Losartan +1 morePhasePhase 4Registry statusCompletedEffect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment
NCT00813722 · start 1999-03
Registered record
- Registry ID
- NCT00813722
- Conditions
- Blood Pressure
- Interventions
- phone call; amlodipine (calcium chanel blocker) and losartan (at1 antagonist); atenolol (beta blocker) and hydrochlorothiazide (diuretic)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 1999-03
- Completion
- 2009-06
- Enrolment
- 400
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBlood PressureInterventionphone call; amlodipine (calcium chanel blocker) and losartan (at1 antagonist); atenolol (beta blocker) and hydrochlorothiazide (diuretic)PhasePhase 4Registry statusUnknownTreatment of Hypertension
NCT00000484 · start 1966-04
Registered record
- Registry ID
- NCT00000484
- Conditions
- Cardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases
- Interventions
- chlorothiazide; Rauwolfia alkaloids
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1966-04
- Completion
- 1979-01
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCardiovascular Diseases; Heart Diseases; Hypertension; Vascular DiseasesInterventionchlorothiazide; Rauwolfia alkaloidsPhasePhase 3Registry statusCompletedBioequivalence Study of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fed Conditions
NCT01218724
Registered record
- Registry ID
- NCT01218724
- Conditions
- Healthy
- Interventions
- Losartan Potassium and Hydrochlorothiazide Tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionLosartan Potassium and Hydrochlorothiazide TabletsPhasePhase 1Registry statusCompleted